Medicine Prices

Despite lower GST rates on most food items and medicines, many consumers report only partial or no price relief, highlighting gaps in implementation and last-mile enforcement, a recent survey said

Retailers say proximity of new outlets is hurting sales and seek higher trade margins along with GST loss compensation under the Jan Aushadhi scheme

A LocalCircles survey finds GST 2.0 benefits have reached only a fraction of consumers, with packaged foods and medicines lagging while vehicles and appliances show clearer price cuts

Chemists' body urges action against e-pharmacies, quick commerce apps for delivering high-risk drugs without checks, warning of rising misuse and youth addiction

Pharmaceuticals Export Promotion Council of India (Pharmexcil) on Thursday said President Donald Trump's imposition of a 25 per cent tariff plus unspecified penalty on all goods coming from India starting August 1, will result in increased costs for essential drugs in the US, ultimately harming consumers and healthcare systems in the country in the long term. The US market, heavily reliant on India for Active Pharmaceutical Ingredients (APIs) and low-cost generics, faces a daunting challenge in finding alternative sources that can match the scale, quality, and affordability that India offers, Pharmexcil Chairman Namit Joshi said in a statement. President Donald Trump on Wednesday announced the imposition of a 25 per cent tariff on all goods coming from India starting August 1, plus an unspecified penalty for buying Russian crude oil and military equipment. Reacting to the development, Joshi said India has long been a cornerstone of the global supply chain for affordable, high-qualit

The NPPA will ensure drug companies do not exceed the 10% annual price increase limit on non-essential medicines

India sees a 50 per cent surge in cardiac drug sales between 2021 and 2025, reflecting a worrying rise in heart disease cases and early diagnoses. Experts call for urgent preventive strategies

Novo and Lilly are both scaling up production as they vie for a dominant share of a weight-loss market that some analysts forecast could reach $150 billion a year in the next decade

Adjusted earnings before interest, taxes and amortisation (EBITA) were exactly in line with expectations at 516 million euros, up 13 per cent year-on-year, as lower costs pushed the profit margin up

Olympus' 6 per cent tumble put the company's shares on track for their biggest one-day fall in nearly three months

Half of the states without coverage said they are considering adding them or evaluating their coverage, it said

Ceiling prices were also revised for the asthma drug Salbutamol in tablets of 2 mg and 4 mg formulations and respirator solution of 5 mg/ml formulation

More than 50 widely prescribed medications, including treatments for high blood pressure, acid reflux, and erectile dysfunction, were identified as substandard in quality

Orchid Pharma's newly-formed antimicrobial solutions division is targeting a turnover of up to Rs 300 crore in the next three years with about 250 strong salespeople onboard while combating the challenge of antimicrobial resistance in India, according to a top company official. Orchid AMS (Antimicrobial Solutions) is targeting to partner with around 2,500-3,000 hospitals and healthcare institutions in the next two to three years to implement effective antimicrobial stewardship programmes (AMSPs). Antimicrobial resistance is one of the biggest healthcare challenges beyond the hospitals as medications are available easily without prescriptions and antibiotics are also coming in through poultry, fish and through crops, Rajnish Rohatgi, CEO, Orchid AMS, a division of Orchid Pharma, told PTI. "This is a humongous issue. We felt that not only from a business aspect of creating a difference but it provides us a motivating purpose beyond business and to give back to society in our own way,

India's current aesthetic medicine market stands at approximately $1.62 billion and is expected to grow at a compound annual growth rate (CAGR) of 13.2 per cent

Lenacapavir drug hailed as 'the closest we have ever been to an HIV vaccine', is currently sold by US pharma major Gilead at Rs $42,250 for the first year

According to an industry source, the committee will also look at ways to design a price moderation framework for medical devices while providing incentives to the medtech industry to minimize imports

Union Minister Mansukh Mandaviya said on Thursday said there will be no increase in prices of essential medicines this fiscal year in view of negligible growth in wholesale price-based inflation. In an interaction with PTI editors at the news agency's headquarters here, Mandaviya -- the Union Chemicals and Fertilisers Minister -- assured that this is "Modiji's guarantee". When asked about reports and speculations of hike in rates of essential drugs, he said, "It is absolutely incorrect. There will be no increase in the price of medicines". The minister said the National Pharmaceutical Pricing Authority (NPPA), which is under the Department of Pharmaceuticals, annually revises the ceiling prices of scheduled medicines on the basis of Wholesale Price Index (WPI). "NPPA monitors and fixes the prices of essential medicines based on WPI," Mandaviya said. When inflation rises, it leads to a hike in prices and when it goes down, the prices come down, the minister said. "This year the ..

This would come after the price hikes allowed (in line with the change in WPI) in the previous two years were 12.12 per cent (2023) and 10.7 per cent (2022) respectively

According to the NCH notification, each existing institution will now have to submit information and relevant annexures needed for the assessment and rating on an annual basis